Downloaded from ijem.sbmu.ac.ir at 15: on Thursday September 6th

Transcript

1 ( ) : (2 (1 : 7 Golbonsohrab@yahoo.com. :.. :. :. HOMA-β HOMA-IR. (P= / ). HOMA-β HOMA-IR.(P= / ).(P= / ) (P= / ) :.. 2 : 96/2/12 : 96/2/4 : 95/11 : (WHO)

2 , / / B A. 13 B A A 50. A B 2.. Curcuma longa (IGF-1) 10. A1c Clinical Trial.gove NCT

3 . B ). B A (.. ( ). 15 B A Arjuna Natural.. Extract Ltd. Nutritionist IV HbA1c EDTA ) Zellbio. (Germany) 38 ( Enzyme-Linked Immunosorbent Monobind Assay (ELISA) HOMA-IR. HOMA-B MUFA(Mono unsaturated fatty Acid) 22. PUFA(Poly unsaturated fatty Acid) HOMA-IR=( (/) ( / ))/22/5 HOMA-B=20 ( / ) / (/)-3/5

4 , (1 ) : 292 : 9 : 192 : 47 : 22 SPSS. ) (. - Paired t-test t-test general linear model 28 : 25 : : 5 : : 3 : : -2 1 : -3 : 4 : : 1 : : -2 2 : -3 : : -1

5 -1 P %39/1 %87 60±7 8±7/9 %43 %43 %35 %17 %52/2 %65/2 %61/9 %81 57±8 8±4/6 %52 %52 %33 %10 %47/6 %66/7 + () () ( ) ( ) () () () P Value..(2 ) ( ) Pvalue (1) ± ± ±26 73± 254±71 5± ±12 26± ± 68± 24 19±5 19± ±9 25±7 20±7 17± ± ±1 95 ±9 20± ± ± ± ± ± 68± ±73 224± ±10 24± ±19 68± ±5 19± ±7 24± ±6 16± ±101 6± ±8 19± ± ± ± ± ±24 64± ±71 247± ±11 26± ±24 71± ±9 19± ±9 24± ±6 17± ± ± ±10 20± ±93 113±71 41 ( / ) ( ) Pvalue ( / ) ( ) Pvalue ( / )/ ( ) Pvalue ( / ) ( ) Pvalue ( / ) ( ) Pvalue ( / ) ( ) Pvalue ( / ) MUFA ( ) Pvalue ( / ) PUFA ( ) Pvalue (/ ) ( ) Pvalue (/ )E ( ) Pvalue (/ )C ( ) Pvalue

6 ,.(P=02). 3 (P=05) -3 P ( ) 144/00± ±35/ /00± /00±33/ 00 3/00±02-7/00±-2/ ( ) 8/36 ±6/04 9/25 ±8/ 96 9/70±4/70 9/46±6/ 54 1/34± -1/34 ± -2/ () 11/26±1/39 11/35±1/ 61 11/18±1/82 11/05±2/ 08-08±43-30± (HOMA-IR) 53/09±418 61/83±63/ 48 65/43±43/57 62/49±41/ 67-12/34±3/39-66± -/ () 74/04±11/95 77/80±13/ 28 74/±12/32 77/16±13/ 06 19±37-64± ( ) 28/27±2/54 29/20±3/ 76 28/32±2/54 28/97±3/ 73 50±00 -± ( ) 96/76±8/ ±8/ 52 96/33±8/09 99/75±8/ 92-43± -11-1/20± ( ) 106/56±5/07 108/52±8/ /02±5/14 107/52±8/ 02 46±07-1/00± (General Linear Model ) p-value ( t ) p-value*. ±

7 3 HbA1c 2 (HOMA-IR) 20. HbA1c (HOMA-IR) HbA1c BMI LDL PPAR AMP 6 GLUT2 GLUT GLUT (P= 01).(P=04) (P=03).. (P=05).(P=01) 2. A 1C A 1C.. i i -Li-Xin

8 , TG 27...(P=01) NFkB TNF-a NFkB NFkB. 6 TNF-a 6 TNF-a. GLUT-4 NFkB A1C i ii HepG i- Nagwa ii -Iwan

9 References 1. World Health Organization, (WHO). Global report on diabetes; Verma S, Hussain ME. Obesity and diabetes: An update. Diabetes Metab Syndr 2017; 11: Adab Z, Eghtesadi Sh, Vafa MR, Heydari I, Shojai A, Haghani H, et al. Effect of turmeric on body measurement indices, glycemic condition, and lipid profile in hyperlipidemic patients with type 2 diabetes. Iranian Journal of Nutrition Sciences and Food Technology 2013: 7-27.[Farsi] 4. Chuengsamarn S, Rattanamongkolgul S, Luechapudiporn R, Phisalaphong C, Jirawatnotai S. Curcumin extract for prevention of type 2 diabetes. Diabetes Care 2012; 35: Jain SK, Rains J, Jones K. Effect of curcumin on protein glycosylation, lipid peroxidation, and oxygen radical generation in human red blood cells exposed to high glucose levels. Free Radical Biol Med 2006; 41: Son Y, Lee JH, Cheong YK, Chung HT, Pae HO. Antidiabetic potential of the heme oxygenase-1 inducer curcumin analogues. Biomed Res Int 2013; 2013: Rivera-Mancia S, Lozada-Garcia MC, Pedraza-Chaverri J. Experimental evidence for curcumin and its analogs for management of diabetes mellitus and its associated complications. Eur J Pharmacol 2015; 756: Soetikno V, Suzuki K, Veeraveedu PT, Arumugam S, Lakshmanan AP, Sone H, et al. Molecular understanding of curcumin in diabetic nephropathy. Drug Discov Today 2013; 18: Bradford PG. Curcumin and obesity. Biofactors 2013; 39: El-Bahr SM. Curcumin regulates gene expression of insulin like growth factor, B-cell CLL/lymphoma 2 and antioxidant enzymes in streptozotocin induced diabetic rats. BMC Complement Altern Med 2013; 13: Seo KI, Choi MS, Jung UJ, Kim HJ, Yeo J, Jeon SM, et al. Effect of curcumin supplementation on blood glucose, plasma insulin, and glucose homeostasis related enzyme activities in diabetic db/db mice. Mol Nutr Food Res 2008; 52: Weisberg SP, Leibel R, Tortoriello DV. Dietary curcumin significantly improves obesity-associated inflammation and diabetes in mouse models of diabesity. Endocrinology 2008; 149: Ghorbani Z, Hekmatdoost A, Mirmiran P. Anti-hyperglycemic and insulin sensitizer effects of turmeric and its principle constituent curcumin. Int J Endocrinol Metab 2014; 12: e Wu W, Geng H, Liu Z, Li H, Zhu Z. Effect of curcumin on rats/mice with diabetic nephropathy: a systematic review and meta-analysis of randomized controlled trials. J Tradit Chin Med 2014; 34: Maradana MR, Thomas R, O'Sullivan BJ. Targeted delivery of curcumin for treating type 2 diabetes. Mol Nutr Food Res 2013; 57: Aldebasi YH, Aly SM, Rahmani AH. Therapeutic implications of curcumin in the prevention of diabetic retinopathy via modulation of anti-oxidant activity and genetic pathways. Int J Physiol pathophysiol Pharmacol 2013; 5: Gupta SK, Kumar B, Nag TC, Agrawal SS, Agrawal R, Agrawal P, et al. Curcumin prevents experimental diabetic retinopathy in rats through its hypoglycemic, antioxidant, and anti-inflammatory mechanisms. J Ocul Pharmacol Ther 2011; 27: Nishiyama T, Mae T, Kishida H, Tsukagawa M, Mimaki Y, Kuroda M, et al. Curcuminoids and sesquiterpenoids in turmeric (Curcuma longa L.) suppress an increase in blood glucose level in type 2 diabetic KK-Ay mice. J Agric Food Chem 2005; 53: Arun N, Nalini N. Efficacy of turmeric on blood sugar and polyol pathway in diabetic albino rats. Plant Foods Hum Nutr 2002; 57: Na LX, Li Y, Pan HZ, Zhou XL, Sun DJ, Meng M, et al. Curcuminoids exert glucose-lowering effect in type 2 diabetes by decreasing serum free fatty acids: a doubleblind, placebo-controlled trial. Mol Nutr Food Res 2013; 57: Kelishadi R, Rabiei K, Khosravi A, Famouri F, Sadeghi M, Rouhafzi H, et al. Assessment of physical activity of adolescents in Isfahan. J Shahrekord Univ Med Sci J 2001, 3: Muniyappa R, Lee S, Chen H, Quon MJ. Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab 2008; 294: E Maithilikarpagaselvi N, Sridhar MG, Swaminathan RP, Zachariah B. Curcumin prevents inflammatory response, oxidative stress and insulin resistance in high fructose fed male Wistar rats: Potential role of serine kinases. Chem Biol Interact 2016; 244: Song Z, Wang H, Zhu L, Han M, Gao Y, Du Y, et al. Curcumin improves high glucose-induced INS-1 cell insulin resistance via activation of insulin signaling. Food Funct 2015; 6: Nagwa A. Ismail S, Salamia E, Regab S, Abeer N. Abd E. Wafaa M. Impact of Curcumin Intake on Gluco- Insulin Homeostasis, Leptin and Adiponectin in Obese Subjects 2016; Alappat L, Awad AB. Curcumin and obesity: evidence and mechanisms. Nutr Rev 2010; 68: Budiman I, Tjokropranoto R, Widowati W, Fauziah N, Erawijantari P. Potency of tumeric (Curcuma longa L.) extract and curcumin as anti-obesity by inhibiting the cholesterol and triglycerides synthesis in HepG2 cells. Int J Res Med Sci 2015; 3: Shehzad A, Ha T, Subhan F, Lee YS. New mechanisms and the anti-inflammatory role of curcumin in obesity and obesity-related metabolic diseases. Eur J Nutr 2011; 50:

10 Vol 19 No.1 April-May 2017 Iranian Journal of Endocrinology and Metabolism / 62 Original Article The Effects of Curcumin Supplementation on Control Glycemic and Anthropometric Indices in Overweight Patients with Type 2 Diabetes Hodaie H 1, Adibian M 1, Sohrab G 1, Hedayati M 2 1 Department of Clinical Nutrition and Dietetics, Faculty of Nutrition Sciences and Food Technology, Shahid Beheshti University of Medical Sciences, 2 Cellular and Molecular Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, I.R. Iran Golbonsohrab@yahoo.com Received: /12/2016 Accepted: 02/05/2017 Abstract Introduction: Experimental observations have shown the effect of curcumin on improving fasting blood glucose and weight loss. Curcumin is a natural yellow plant (stem), which exhibits various biological activities such as anti-oxidant, anti-carcinogenic, and anti-diabetic effects. The aim of this study was to investigate the effect of curcumin supplementation on glycemic control and anthropometric indices in overweight patients with type 2 diabetes. Materials and Methods: In this randomized, double-blind, placebo-controlled trial, 53 participants with type 2 diabetes were divided randomly into the experimental and control groups to receive either 500mg curcumin or placebo capsule three times in a day for 10 weeks. Anthropometric measures including weight, height, waist circumference, hip circumference and BMI, serum levels of fasting blood sugar (FBS), Hemoglobin A1c (HbA1c), insulin, HOMA-IR and HOMA-β were determined at baseline and again 10 weeks later. Result: There were no significant differences between the two groups with regard to mean age, duration of diabetes, treatment method, drugs and sex distribution. At the end of the study the mean serum concentration of blood sugar decreased significantly between the two groups (p=0.01). Mean serum concentrations of insulin, HbA1C, HOMA-IR and HOMA-β showed no significant changes between two groups at the end of the study. Mean body weight decreased significantly in the curcumin group, compared to the controls at the end of the study (p=0.04). Mean hip circumference decreased significantly in curcumin group at the end of the study compared to the baseline (p=0.05), a difference that was significant in curcumin group, compared to the placebo group (p=0.01). At the end of the study the mean waist circumference had no significant difference between the two groups. Conclusion: This study indicated that daily administration of 1500 mg curcumin has positive effects in reducing fasting blood glucose and weight in patients with type 2 diabetes. Keywords: Curcumin, Diabetes, Weight lost, Glycemic control